Related Experiment Video
Updated: May 23, 2026

An Open-Source Framework for Mass Calculation of Antibody-Based Therapeutic Molecules
Published on: June 16, 2023
Biosimilar, biobetter, and next generation antibody characterization by mass spectrometry
Alain Beck1, Sarah Sanglier-Cianférani, Alain Van Dorsselaer
1Centre d'Immunologie Pierre Fabre (CIPF), 5 Av. Napoléon III, BP 60497, 74164 Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
Abstract:
This Feature will introduce the strategies of therapeutic antibodies (mAbs) in-depth characterization by mass spectrometry (MS) and discuss analytical comparison of biosimilar to originator mAbs, with the cases of trastuzumab and cetuximab. In addition, the structural and functional insights gained both by state-of-the art and emerging MS methods used for biobetters and next generation antibodies design and optimization will also be highlighted.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Peptide Identification Using Tandem Mass Spectrometry
This technique helps gather information regarding the protein from which the peptide was obtained and to study the peptides’ amino acid sequence. Identifying peptides from a complex mixture is an important component of the growing field of...
MALDI-TOF Mass Spectrometry

